Tyra Biosciences, Inc. (TYRA) Research

Tyra Biosciences, Inc. is a preclinical biopharmaceutical company focused on innovating treatments to tackle tumor resistance and enhance patient outcomes in oncology. Its flagship product candidate, TYRA-300, is a highly selective inhibitor of fibroblast growth factor receptor (FGFR)3, specifically engineered for the treatment of muscle-invasive bladder cancer. Beyond this, the company is advancing a pipeline of programs addressing other critical conditions, including FGFR2-related intrahepatic cholangiocarcinoma, FGFR3-associated achondroplasia, REarranged during transfection (RET) kinase aberrations, and various FGFR4-driven cancers. Tyra also leverages its proprietary SNAP platform, designed to accelerate structural drug design through an iterative molecular 'snapshot' approach. Founded in 2018, Tyra Biosciences maintains its headquarters in Carlsbad, California.

Market snapshot

Symbol
TYRA
Price
$28.32
Day change
-2.58%
Market cap
$1.7B
P/E ratio
-13.34x
52-week range
8.98-40.65
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$50.50

Peer companies

  • Day One Biopharmaceuticals, Inc. (DAWN)
  • EyePoint Pharmaceuticals, Inc. (EYPT)
  • Geron Corporation (GERN)
  • Kura Oncology, Inc. (KURA)
  • Maravai LifeSciences Holdings, Inc. (MRVI)
  • Nanobiotix S.A. (NBTX)
  • Prime Medicine, Inc. (PRME)
  • ProKidney Corp. (PROK)

Recent insider activity

  • RA CAPITAL MANAGEMENT, L.P. — A-Award (13160 shares) on 2026-05-28
  • Verjee Rehan — A-Award (13160 shares) on 2026-05-28
  • Moran Susan — A-Award (13160 shares) on 2026-05-28
  • Simson Jake — A-Award (13160 shares) on 2026-05-28
  • Gulfo Adele M. — A-Award (13160 shares) on 2026-05-28

Open Tyra Biosciences, Inc. (TYRA) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.